Investigation of factors influencing the immunogenicity of hCG as a potential cancer vaccine

Nino Kvirkvelia, N. Chikadze, J. Makinde, J. D. McBride, N. Porakishvili, F. A. Hills, P. M. Martensen, J. Justesen, P. J. Delves, T. Lund, I. M. Roitt

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Human chorionic gonadotrophin (hCG) and its β-subunit (hCGβ) are tumour autocrine growth factors whose presence in the serum of cancer patients has been linked to poorer prognosis. Previous studies have shown that vaccines which target these molecules and/or the 37 amino acid C-terminal hCGβ peptide (hCGβCTP) induce antibody responses in a majority of human recipients. Here we explored whether the immunogenicity of vaccines containing an hCGβ mutant (hCGβR68E, designed to eliminate cross-reactivity with luteinizing hormone) or hCGβCTP could be enhanced by coupling the immunogen to different carriers [keyhole limpet haemocyanin (KLH) or heat shock protein 70 (Hsp70)] using different cross-linkers [1-ethyl-3(3-dimethylaminopropyl)carboiimide (EDC) or glutaraldehyde (GAD)] and formulated with different adjuvants (RIBI or Montanide ISA720). While there was little to choose between KLH and Hsp70 as carriers, their influence on the effectiveness of a vaccine containing the BAChCGβR68E mutant was less marked, presumably because, being a foreign species, this mutant protein itself might provide T helper epitopes. The mutant provided a significantly better vaccine than the hCGβCTP peptide irrespective of the carrier used, how it was cross-linked to the carrier or which adjuvant was used when hCG was the target. Nonetheless, for use in humans where hCG is a tolerated self-protein, the need for a carrier is of fundamental importance. Highest antibody titres were obtained by linking the BAChCGβR68E to Hsp70 as a carrier by GAD and using RIBI as the adjuvant, which also resulted in antibodies with significantly higher affinity than those elicited by hCGβCTP peptide vaccine. This makes this mutant vaccine a promising candidate for therapeutic studies in hCGβ-positive cancer patients.

Original languageEnglish (US)
Pages (from-to)73-83
Number of pages11
JournalClinical and Experimental Immunology
Volume193
Issue number1
DOIs
StatePublished - Jul 1 2018

Fingerprint

Cancer Vaccines
Chorionic Gonadotropin
HSP70 Heat-Shock Proteins
Subunit Vaccines
Vaccines
Glutaral
Neoplasms
Antibodies
Mutant Proteins
Luteinizing Hormone
Antibody Formation
Epitopes
Intercellular Signaling Peptides and Proteins
Amino Acids
Peptides
Serum

Keywords

  • B cell response
  • Hsp70
  • adjuvant
  • cancer vaccine
  • human chorionic gonadotrophin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Kvirkvelia, N., Chikadze, N., Makinde, J., McBride, J. D., Porakishvili, N., Hills, F. A., ... Roitt, I. M. (2018). Investigation of factors influencing the immunogenicity of hCG as a potential cancer vaccine. Clinical and Experimental Immunology, 193(1), 73-83. https://doi.org/10.1111/cei.13131

Investigation of factors influencing the immunogenicity of hCG as a potential cancer vaccine. / Kvirkvelia, Nino; Chikadze, N.; Makinde, J.; McBride, J. D.; Porakishvili, N.; Hills, F. A.; Martensen, P. M.; Justesen, J.; Delves, P. J.; Lund, T.; Roitt, I. M.

In: Clinical and Experimental Immunology, Vol. 193, No. 1, 01.07.2018, p. 73-83.

Research output: Contribution to journalArticle

Kvirkvelia, N, Chikadze, N, Makinde, J, McBride, JD, Porakishvili, N, Hills, FA, Martensen, PM, Justesen, J, Delves, PJ, Lund, T & Roitt, IM 2018, 'Investigation of factors influencing the immunogenicity of hCG as a potential cancer vaccine', Clinical and Experimental Immunology, vol. 193, no. 1, pp. 73-83. https://doi.org/10.1111/cei.13131
Kvirkvelia N, Chikadze N, Makinde J, McBride JD, Porakishvili N, Hills FA et al. Investigation of factors influencing the immunogenicity of hCG as a potential cancer vaccine. Clinical and Experimental Immunology. 2018 Jul 1;193(1):73-83. https://doi.org/10.1111/cei.13131
Kvirkvelia, Nino ; Chikadze, N. ; Makinde, J. ; McBride, J. D. ; Porakishvili, N. ; Hills, F. A. ; Martensen, P. M. ; Justesen, J. ; Delves, P. J. ; Lund, T. ; Roitt, I. M. / Investigation of factors influencing the immunogenicity of hCG as a potential cancer vaccine. In: Clinical and Experimental Immunology. 2018 ; Vol. 193, No. 1. pp. 73-83.
@article{097b4cf698e4489d9de77c397aa5859a,
title = "Investigation of factors influencing the immunogenicity of hCG as a potential cancer vaccine",
abstract = "Human chorionic gonadotrophin (hCG) and its β-subunit (hCGβ) are tumour autocrine growth factors whose presence in the serum of cancer patients has been linked to poorer prognosis. Previous studies have shown that vaccines which target these molecules and/or the 37 amino acid C-terminal hCGβ peptide (hCGβCTP) induce antibody responses in a majority of human recipients. Here we explored whether the immunogenicity of vaccines containing an hCGβ mutant (hCGβR68E, designed to eliminate cross-reactivity with luteinizing hormone) or hCGβCTP could be enhanced by coupling the immunogen to different carriers [keyhole limpet haemocyanin (KLH) or heat shock protein 70 (Hsp70)] using different cross-linkers [1-ethyl-3(3-dimethylaminopropyl)carboiimide (EDC) or glutaraldehyde (GAD)] and formulated with different adjuvants (RIBI or Montanide ISA720). While there was little to choose between KLH and Hsp70 as carriers, their influence on the effectiveness of a vaccine containing the BAChCGβR68E mutant was less marked, presumably because, being a foreign species, this mutant protein itself might provide T helper epitopes. The mutant provided a significantly better vaccine than the hCGβCTP peptide irrespective of the carrier used, how it was cross-linked to the carrier or which adjuvant was used when hCG was the target. Nonetheless, for use in humans where hCG is a tolerated self-protein, the need for a carrier is of fundamental importance. Highest antibody titres were obtained by linking the BAChCGβR68E to Hsp70 as a carrier by GAD and using RIBI as the adjuvant, which also resulted in antibodies with significantly higher affinity than those elicited by hCGβCTP peptide vaccine. This makes this mutant vaccine a promising candidate for therapeutic studies in hCGβ-positive cancer patients.",
keywords = "B cell response, Hsp70, adjuvant, cancer vaccine, human chorionic gonadotrophin",
author = "Nino Kvirkvelia and N. Chikadze and J. Makinde and McBride, {J. D.} and N. Porakishvili and Hills, {F. A.} and Martensen, {P. M.} and J. Justesen and Delves, {P. J.} and T. Lund and Roitt, {I. M.}",
year = "2018",
month = "7",
day = "1",
doi = "10.1111/cei.13131",
language = "English (US)",
volume = "193",
pages = "73--83",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Investigation of factors influencing the immunogenicity of hCG as a potential cancer vaccine

AU - Kvirkvelia, Nino

AU - Chikadze, N.

AU - Makinde, J.

AU - McBride, J. D.

AU - Porakishvili, N.

AU - Hills, F. A.

AU - Martensen, P. M.

AU - Justesen, J.

AU - Delves, P. J.

AU - Lund, T.

AU - Roitt, I. M.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Human chorionic gonadotrophin (hCG) and its β-subunit (hCGβ) are tumour autocrine growth factors whose presence in the serum of cancer patients has been linked to poorer prognosis. Previous studies have shown that vaccines which target these molecules and/or the 37 amino acid C-terminal hCGβ peptide (hCGβCTP) induce antibody responses in a majority of human recipients. Here we explored whether the immunogenicity of vaccines containing an hCGβ mutant (hCGβR68E, designed to eliminate cross-reactivity with luteinizing hormone) or hCGβCTP could be enhanced by coupling the immunogen to different carriers [keyhole limpet haemocyanin (KLH) or heat shock protein 70 (Hsp70)] using different cross-linkers [1-ethyl-3(3-dimethylaminopropyl)carboiimide (EDC) or glutaraldehyde (GAD)] and formulated with different adjuvants (RIBI or Montanide ISA720). While there was little to choose between KLH and Hsp70 as carriers, their influence on the effectiveness of a vaccine containing the BAChCGβR68E mutant was less marked, presumably because, being a foreign species, this mutant protein itself might provide T helper epitopes. The mutant provided a significantly better vaccine than the hCGβCTP peptide irrespective of the carrier used, how it was cross-linked to the carrier or which adjuvant was used when hCG was the target. Nonetheless, for use in humans where hCG is a tolerated self-protein, the need for a carrier is of fundamental importance. Highest antibody titres were obtained by linking the BAChCGβR68E to Hsp70 as a carrier by GAD and using RIBI as the adjuvant, which also resulted in antibodies with significantly higher affinity than those elicited by hCGβCTP peptide vaccine. This makes this mutant vaccine a promising candidate for therapeutic studies in hCGβ-positive cancer patients.

AB - Human chorionic gonadotrophin (hCG) and its β-subunit (hCGβ) are tumour autocrine growth factors whose presence in the serum of cancer patients has been linked to poorer prognosis. Previous studies have shown that vaccines which target these molecules and/or the 37 amino acid C-terminal hCGβ peptide (hCGβCTP) induce antibody responses in a majority of human recipients. Here we explored whether the immunogenicity of vaccines containing an hCGβ mutant (hCGβR68E, designed to eliminate cross-reactivity with luteinizing hormone) or hCGβCTP could be enhanced by coupling the immunogen to different carriers [keyhole limpet haemocyanin (KLH) or heat shock protein 70 (Hsp70)] using different cross-linkers [1-ethyl-3(3-dimethylaminopropyl)carboiimide (EDC) or glutaraldehyde (GAD)] and formulated with different adjuvants (RIBI or Montanide ISA720). While there was little to choose between KLH and Hsp70 as carriers, their influence on the effectiveness of a vaccine containing the BAChCGβR68E mutant was less marked, presumably because, being a foreign species, this mutant protein itself might provide T helper epitopes. The mutant provided a significantly better vaccine than the hCGβCTP peptide irrespective of the carrier used, how it was cross-linked to the carrier or which adjuvant was used when hCG was the target. Nonetheless, for use in humans where hCG is a tolerated self-protein, the need for a carrier is of fundamental importance. Highest antibody titres were obtained by linking the BAChCGβR68E to Hsp70 as a carrier by GAD and using RIBI as the adjuvant, which also resulted in antibodies with significantly higher affinity than those elicited by hCGβCTP peptide vaccine. This makes this mutant vaccine a promising candidate for therapeutic studies in hCGβ-positive cancer patients.

KW - B cell response

KW - Hsp70

KW - adjuvant

KW - cancer vaccine

KW - human chorionic gonadotrophin

UR - http://www.scopus.com/inward/record.url?scp=85046548130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046548130&partnerID=8YFLogxK

U2 - 10.1111/cei.13131

DO - 10.1111/cei.13131

M3 - Article

AN - SCOPUS:85046548130

VL - 193

SP - 73

EP - 83

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 1

ER -